Jenni S Liikanen1, Marjut Leidenius1, Heikki Joensuu2, Tuomo J Meretoja1. 1. Comprehensive Cancer Center, Breast Surgery Unit, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 2. Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Abstract
Introduction: Human epidermal growth factor receptor 2 (HER2) expression is considered an unfavourable prognostic factor in early breast cancer when the patients are not treated with HER2-targeted therapy. However, the long-term prognostic importance of HER2 expression in small (≤1 cm, stage pT1a-b), node-negative HER2* breast cancer is still incompletely known. Methods: A retrospective analysis was performed based on a prospectively collected database including patients with pT1 breast cancer operated at the Helsinki University Hospital, Finland, between March 2000 and April 2006. In this database, 44 patients with pT1a-bN0M0, HER2* cancer, not treated with adjuvant anti-HER2-targeted therapy (the HER2* group) and 291 pT1a-bN0M0, hormone receptor-positive, HER2-negative cancers (the ER*/HER2- group) were identified and included in the study. Survival outcomes were analysed using the Kaplan-Meier method. Results: The median follow-up time was 9.7 years after primary breast surgery. Ten-year distant disease-free survival (DDFS) was 84.0% in the HER2* group and 98.2% in the ER*/HER2- group (p < 0.001). Ten-year overall survival was only 78.5% in the HER2* group, but 91.7% in the ER*/HER2- group (p = 0.09). Conclusions: Cancer HER2 status is strongly associated with unfavourable DDFS during the first decade of follow-up in patients with small (pT1a-bN0M0) breast cancer when adjuvant anti-HER2-targeted treatment is not administered.
Introduction: Human epidermal growth factor receptor 2 (HER2) expression is considered an unfavourable prognostic factor in early breast cancer when the patients are not treated with HER2-targeted therapy. However, the long-term prognostic importance of HER2 expression in small (≤1 cm, stage pT1a-b), node-negative HER2* breast cancer is still incompletely known. Methods: A retrospective analysis was performed based on a prospectively collected database including patients with pT1 breast cancer operated at the Helsinki University Hospital, Finland, between March 2000 and April 2006. In this database, 44 patients with pT1a-bN0M0, HER2* cancer, not treated with adjuvant anti-HER2-targeted therapy (the HER2* group) and 291 pT1a-bN0M0, hormone receptor-positive, HER2-negative cancers (the ER*/HER2- group) were identified and included in the study. Survival outcomes were analysed using the Kaplan-Meier method. Results: The median follow-up time was 9.7 years after primary breast surgery. Ten-year distant disease-free survival (DDFS) was 84.0% in the HER2* group and 98.2% in the ER*/HER2- group (p < 0.001). Ten-year overall survival was only 78.5% in the HER2* group, but 91.7% in the ER*/HER2- group (p = 0.09). Conclusions: Cancer HER2 status is strongly associated with unfavourable DDFS during the first decade of follow-up in patients with small (pT1a-bN0M0) breast cancer when adjuvant anti-HER2-targeted treatment is not administered.
Authors: F Cardoso; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; I T Rubio; S Zackrisson; E Senkus Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: Ciara C O'Sullivan; Ian Bradbury; Christine Campbell; Marc Spielmann; Edith A Perez; Heikki Joensuu; Joseph P Costantino; Suzette Delaloge; Priya Rastogi; Dimitrios Zardavas; Karla V Ballman; Eileen Holmes; Evandro de Azambuja; Martine Piccart-Gebhart; Jo Anne Zujewski; Richard D Gelber Journal: J Clin Oncol Date: 2015-06-22 Impact factor: 44.544
Authors: T Kolben; N Harbeck; R Wuerstlein; G Schubert-Fritschle; I Bauerfeind; S Schrodi; J Engel Journal: Breast Date: 2014-11-08 Impact factor: 4.380
Authors: Louis Fehrenbacher; Angela M Capra; Charles P Quesenberry; Regan Fulton; Parveen Shiraz; Laurel A Habel Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Birgitte B Rasmussen; Meredith M Regan; Anne E Lykkesfeldt; Patrizia Dell'Orto; Barbara Del Curto; Katrine L Henriksen; Mauro G Mastropasqua; Karen N Price; Eliane Méry; Magali Lacroix-Triki; Stephen Braye; Hans J Altermatt; Richard D Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Barry A Gusterson; Beat Thürlimann; Alan S Coates; Giuseppe Viale Journal: Lancet Oncol Date: 2007-12-20 Impact factor: 41.316